var data={"title":"Pegloticase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegloticase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/430050?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegloticase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegloticase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302844\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Anaphylaxis and infusion reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylaxis and infusion reactions have been reported to occur during and after administration of pegloticase. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. Pegloticase should be administered in health care settings by health care providers prepared to manage anaphylaxis and infusion reactions</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for anaphylaxis for an appropriate period of time after pegloticase administration. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">G6PD deficiency-associated hemolysis and methemoglobinemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Screen patients at risk for G6PD deficiency prior to starting pegloticase. Hemolysis and methemoglobinemia have been reported with pegloticase in patients with G6PD deficiency. Do not administer pegloticase to patients with G6PD deficiency.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302849\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Krystexxa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806144\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme;</li>\n      <li>\n        Enzyme, Urate-Oxidase (Recombinant)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302955\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Discontinue use of oral antihyperuricemic agents prior to initiating pegloticase and do not initiate during the course of therapy. Premedicate with antihistamines and corticosteroids. Gout flare prophylaxis with either NSAIDs or colchicine is also recommended, beginning at least 1 week prior to initiation and continuing for at least 6 months.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <b>Gout:</b> IV: 8 mg every 2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302956\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302957\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22151409\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11303005\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Krystexxa: 8 mg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302850\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302846\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM227568.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68eUC7cwKdeD/CXuOeFYNswA==&amp;TOPIC_ID=16076\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM227568.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11303884\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer diluted solution by IV infusion over &ge;120 minutes via gravity feed or an infusion pump or syringe-type pump. Do <b>not</b> administer by IV push or bolus. Administer in a healthcare setting by healthcare providers prepared to manage potential anaphylaxis. Monitor closely for infusion reactions during infusion and for an appropriate period of time after the infusion (anaphylaxis has been reported within 2 hours of the infusion). In the event of a less severe infusion reaction, infusion may be slowed, or stopped and restarted at a slower rate, based on the discretion of the physician.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806146\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout:</b> Treatment of chronic gout in adults refractory to conventional therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not for the treatment of asymptomatic hyperuricemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302908\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gout (flare: 74%; within the first 3 months)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (antipegloticase antibodies: 92%; anti-PEG antibodies: 42%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion-related reaction (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (6% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (10%), pruritus (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (6%), vomiting (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis (&le;7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (7%), nasopharyngitis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Nephrolithiasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302855\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Glucose-6-phosphate dehydrogenase (G6PD) deficiency </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302856\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylaxis and infusion reactions have been reported during and after administration; patients should be closely monitored during infusion and for an appropriate period of time after the infusion. Therapy should be administered in a health care facility by skilled medical personnel prepared for the immediate treatment of anaphylaxis. All patients should be premedicated with antihistamines and corticosteroids. Anaphylaxis may occur at any time during treatment (including the initial dose). Reactions generally occur within 2 hours of administration; however, delayed hypersensitivity reactions have also been reported.</b> Infusion reactions are varied; symptoms range from chest pain, pruritus/urticaria, or dyspnea to a clinical presentation of anaphylaxis (eg, hemodynamic instability, perioral or lingual edema). If a less severe (nonanaphylactic) infusion reaction occurs, the infusion may be slowed, or stopped and restarted at a slower rate, at the physician&rsquo;s discretion. Risk of an infusion reaction is increased in patients whose uric acid is &gt;6 mg/dL; therefore, <b>monitor serum uric acid concentrations prior to infusion and consider discontinuing treatment if concentrations exceed 6 mg/dL, particularly in the event of 2 consecutive concentrations &gt;6 mg/dL.</b> Since oral antihyperuricemic agents may blunt the rise of serum uric acid levels, discontinue use prior to and do not initiate during the course of pegloticase therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout flares: Therapy with antihyperuricemic agents commonly results in gout flare, particularly upon initiation due to rapid lowering of urate concentrations; gout flare-ups during treatment do not warrant discontinuation of therapy. Gout flare prophylaxis is recommended, using nonsteroidal anti-inflammatory agents (NSAID) or colchicine, unless contraindicated, beginning &ge;1 week before initiation of pegloticase and continuing for at least 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Exacerbation of heart failure has been observed in clinical trials; use caution in patients with preexisting heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: <b>[US Boxed Warning]: </b><b>Life-threatening hemolytic reactions and methemoglobinemia have been reported with pegloticase in patients with G6PD deficiency. Due to the risk for hemolysis and methemoglobinemia, pegloticase is contraindicated in patients with G6PD deficiency.</b> Patients at increased risk for G6PD deficiency (eg, African, Mediterranean [including Southern European and Middle Eastern], and Southern Asian ancestry) should be screened prior to initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral antihyperuricemic agents: Use with oral antihyperuricemic agents may delay interpretations of ineffective pegloticase treatment (ie, serum uric acid &gt;6 mg/dL) and ultimately increase risk for anaphylactoid and/or infusion reactions. Discontinue use of oral antihyperuricemic agents prior to and do not initiate during the course of pegloticase therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunogenicity: Potential for immunogenicity exists with the use of therapeutic proteins. Antipegloticase antibodies and antiPEG antibodies commonly occurred during clinical trials in pegloticase-treated patients. High antipegloticase antibody titers were associated with failure to maintain uric acid normalization and were also associated with a higher incidence of infusion reactions. Due to potential for immunogenicity, closely monitor patients who reinitiate therapy after discontinuing treatment for &gt;4 weeks; patients may be at increased risk for anaphylaxis and infusion reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299831\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11358648\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16076&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May enhance the adverse/toxic effect of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Pegloticase may diminish the therapeutic effect of Certolizumab Pegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May enhance the adverse/toxic effect of Pegloticase. Specifically, Febuxostat may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegademase Bovine: Pegloticase may diminish the therapeutic effect of Pegademase Bovine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegaptanib: Pegloticase may diminish the therapeutic effect of Pegaptanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegaspargase: Pegloticase may diminish the therapeutic effect of Pegaspargase. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegfilgrastim: Pegloticase may diminish the therapeutic effect of Pegfilgrastim. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2a: Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2a. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: Pegloticase may diminish the therapeutic effect of Peginterferon Alfa-2b. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Pegloticase may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302851\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302852\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302854\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pegloticase is excreted in breast milk. The manufacturer does not recommend breast-feeding unless the potential benefit to the mother is greater than the possible risk to the infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26629267\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum uric acid levels (prior to infusions; consider discontinuation if levels increase to &gt;6 mg/dL, especially if two consecutive levels of &gt;6 mg/dL are observed); infusion reactions and anaphylaxis (during infusion and post-infusion), G6PD deficiency screening (in patients at high risk for deficiency)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11303004\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uric acid, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal values:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 3.4 to 7 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 2.4 to 6 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Goal during therapy: &lt;6 mg/dL; &lt;5 mg/dL in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (ACR [Khanna 2012]; EULAR [Richette 2017]). Levels &lt;3 mg/dL are not recommended long-term (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Serum uric acid values &gt;7 mg/dL do not necessarily represent clinical gout; current clinical practice guidelines do not address pharmacologic management of asymptomatic hyperuricemia (ACR guidelines [Khanna 2012]; EULAR [Richette 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302944\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pegloticase is a pegylated recombinant form of urate-oxidase enzyme, also known as uricase (an enzyme normally absent in humans and high primates), which converts uric acid to allantoin (an inactive and water soluble metabolite of uric acid); it does not inhibit the formation of uric acid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11302946\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~24 hours following the first dose, serum uric acid concentrations decreased</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &gt;300 hours (12.5 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Median: ~14 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as allantoin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322866\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Krystexxa Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (1 mL): $24,507.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671481\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Krystexxa (CZ, DK, EE, FI, IE, LT, MT, NL, PT, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dalbeth N and So A, &ldquo;Hyperuricaemia and Gout: State of the Art and Future Perspectives,&rdquo; <i>Ann Rheum Dis</i>, 2010, 69(10):1738-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/20858623/pubmed\" target=\"_blank\" id=\"20858623\">20858623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care Res (Hoboken).</i> 2012;64(10):1431-1446. doi: 10.1002/acr.21772.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/23024028/pubmed\" target=\"_blank\" id=\"23024028\">23024028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krystexxa (pegloticase) [prescribing information]. Glendale, WI: Crealta Pharmaceuticals LLC; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sundy JS, Becker MA, Baraf HS, et al, &ldquo;Reduction of Plasma Urate Levels following Treatment With Multiple Doses of Pegloticase (Polyethylene Glycol-Conjugated Uricase) in Patients With Treatment-Failure Gout: Results of a Phase II Randomized Study,&rdquo; <i>Arthritis Rheum</i>, 2008, 58(9):2882-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/18759308/pubmed\" target=\"_blank\" id=\"18759308\">18759308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whelton A, &ldquo;Current and Future Therapeutic Options for the Management of Gout,&rdquo; <i>Am J Ther</i>, 2010, 17(4):402-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/20562597/pubmed\" target=\"_blank\" id=\"20562597\">20562597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yue CS, Huang W, Alton M, et al, &ldquo;Population Pharmacokinetic and Pharmacodynamic Analysis of Pegloticase in Subjects With Hyperuricemia and Treatment-Failure Gout,&rdquo; <i>J Clin Pharmacol</i>, 2008, 48(6):708-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegloticase-drug-information/abstract-text/18420531/pubmed\" target=\"_blank\" id=\"18420531\">18420531</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16076 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F11302844\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F11302849\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F10806144\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11302955\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F11302956\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11302957\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22151409\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11303005\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F11302850\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11302846\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11303884\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10806146\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11302908\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11302855\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11302856\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299831\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11358648\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F11302851\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11302852\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11302854\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26629267\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F11303004\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11302944\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11302946\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322866\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671481\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16076|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegloticase-patient-drug-information\" class=\"drug drug_patient\">Pegloticase: Patient drug information</a></li></ul></div></div>","javascript":null}